Weng, LeihuaCao, XiangHan, LijuanZhao, HaoranQiu, ShuweiYan, YapingWang, XiaoyingChen, XiangyanZheng, WeihongXu, XinGao, YuanyuanChen, YanLi, JieYang, YongboXu, Yun2017-07-242017Weng, L., X. Cao, L. Han, H. Zhao, S. Qiu, Y. Yan, X. Wang, et al. 2017. “Association of increased Treg and Th17 with pathogenesis of moyamoya disease.” Scientific Reports 7 (1): 3071. doi:10.1038/s41598-017-03278-8. http://dx.doi.org/10.1038/s41598-017-03278-8.http://nrs.harvard.edu/urn-3:HUL.InstRepos:33490858Immuno-inflammation has been shown to play a pivotal role in the pathogenesis of moyamoya disease (MMD). However, how did circulating Treg/Th17 cells involve in MMD patients remains unclear. 26 MMD, 21 atherothrombotic stroke, and 32 healthy controls were enrolled in this study. MMD patients have a significantly higher percentage of circulating Treg and Th17 cells as well as their dominantly secreting cytokines than other groups (P < 0.0001), whereas no difference was found in the ratio of Treg/Th17 between patients in MMD and atherothrombotic stroke group or control subjects (P = 0.244). However, the increased Treg in MMD patients which were enriched with FrIII Treg cells had deficient suppressive functions (P = 0.0017) compared to healthy volunteers. There was a positive correlation between Treg or TGF-β and MMD Suzuki’s stage. And the level of circulating Treg was as an independent factor associated with MMD stage. Besides, TGF-β was also correlated with the increased expression of VEGF in MMD patients. Our findings indicated an important involvement of circulating Treg in the pathogenic development of MMD and TGF-β in Treg induced VEGF.en-USJournal Article2017-07-2410.1038/s41598-017-03278-8